News

SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL). Sensorion initiated the Phase 2 clinical trial in this indication beginning of 2019 in

As per terms of the deal, Galapagos will secure $3.95bn (£3.5bn) upfront payment and $1.1bn (£874m) equity investment from Gilead. It intends to use the proceeds to expand

Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH

The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumours. The first patient was treated with SO-C101

The partnership will discontinue the evaluation of CNP520 in two pivotal phase II/III studies in the Alzheimer’s Prevention Initiative Generation Programme. According to Novartis, an evaluation of unblinded

The TANGO study was conducted to assess whether adults living with HIV-1 who had maintained viral suppression for at least six months on a tenofovir alafenamide fumarate (TAF)-containing

An investigational monoclonal antibody, isatuximab, has been designed to target a specific epitope on the CD38 receptor of a plasma cell. The drug has been designed to activate

Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz.  Jazz will be responsible for further development, regulatory activities and commercialisation. Under

Nexus has entered into an agreement with Wisconsin’s village Pleasant Prairie for the development of a sterile injectable manufacturing facility. Expected to be completed in 10 years, the